KR101697801B1 - 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물 - Google Patents

2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물 Download PDF

Info

Publication number
KR101697801B1
KR101697801B1 KR1020117026185A KR20117026185A KR101697801B1 KR 101697801 B1 KR101697801 B1 KR 101697801B1 KR 1020117026185 A KR1020117026185 A KR 1020117026185A KR 20117026185 A KR20117026185 A KR 20117026185A KR 101697801 B1 KR101697801 B1 KR 101697801B1
Authority
KR
South Korea
Prior art keywords
compound
dose
trifluoro
methyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117026185A
Other languages
English (en)
Korean (ko)
Other versions
KR20110136893A (ko
Inventor
앨리슨 필그림
제임스 에프 화이트
나디아 엠 제이 러프니악
Original Assignee
코루시드 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42826711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101697801(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코루시드 파마슈티컬즈 인코포레이티드 filed Critical 코루시드 파마슈티컬즈 인코포레이티드
Publication of KR20110136893A publication Critical patent/KR20110136893A/ko
Application granted granted Critical
Publication of KR101697801B1 publication Critical patent/KR101697801B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117026185A 2009-04-02 2010-04-02 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물 Active KR101697801B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16609709P 2009-04-02 2009-04-02
US61/166,097 2009-04-02
PCT/US2010/029810 WO2010115125A2 (en) 2009-04-02 2010-04-02 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Publications (2)

Publication Number Publication Date
KR20110136893A KR20110136893A (ko) 2011-12-21
KR101697801B1 true KR101697801B1 (ko) 2017-01-18

Family

ID=42826711

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026185A Active KR101697801B1 (ko) 2009-04-02 2010-04-02 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물

Country Status (26)

Country Link
US (3) US20100256187A1 (enExample)
EP (1) EP2413933B2 (enExample)
JP (9) JP5727457B2 (enExample)
KR (1) KR101697801B1 (enExample)
CN (2) CN102753171A (enExample)
AU (1) AU2010232497B2 (enExample)
CA (1) CA2757019C (enExample)
CY (2) CY1119785T1 (enExample)
DK (1) DK2413933T4 (enExample)
ES (1) ES2655881T5 (enExample)
FI (1) FIC20230001I1 (enExample)
FR (1) FR23C1002I2 (enExample)
HK (1) HK1243923A1 (enExample)
HR (1) HRP20171742T4 (enExample)
HU (2) HUE037261T2 (enExample)
IL (1) IL215483A (enExample)
LT (2) LT2413933T (enExample)
LU (1) LUC00295I2 (enExample)
MX (1) MX2011010359A (enExample)
NL (1) NL301214I2 (enExample)
NO (2) NO2413933T3 (enExample)
NZ (1) NZ596161A (enExample)
PL (1) PL2413933T5 (enExample)
PT (1) PT2413933T (enExample)
SI (1) SI2413933T2 (enExample)
WO (1) WO2010115125A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
KR101683042B1 (ko) 2008-04-04 2016-12-06 포사이트 비젼4, 인크. 통증 관리 및 시력을 위한 치료 장치
JP5727457B2 (ja) * 2009-04-02 2015-06-03 コルーシッド ファーマシューティカルズ， インコーポレイテッド ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
UA124433C2 (uk) 2016-12-06 2021-09-15 Колюсід Фармасьютікалз, Інк. Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
WO2022086756A1 (en) 2020-10-19 2022-04-28 Journey1, Inc. Astigmatism correcting contact lenses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084949A1 (en) * 2002-03-29 2003-10-16 Eli Lilly And Company Pyridinoylpiperidines as 5-ht1f agonists
WO2006081127A2 (en) * 2005-01-24 2006-08-03 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
KR19980703048A (ko) 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
NZ334031A (en) 1996-08-28 2000-07-28 Lilly Co Eli Migraine treatment using substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2- aminocyclohepta[b]benzofurans
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
CA2360164A1 (en) 1999-02-10 2000-08-17 Eli Lilly And Company 5-ht1f agonists
JP2002537398A (ja) 1999-02-26 2002-11-05 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
JP5265838B2 (ja) 2000-07-13 2013-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな化合物ｉ
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) * 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
EP1581498A2 (en) * 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
JP2006523692A (ja) * 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
KR20060067738A (ko) * 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
JP5727457B2 (ja) 2009-04-02 2015-06-03 コルーシッド ファーマシューティカルズ， インコーポレイテッド ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
UA124433C2 (uk) 2016-12-06 2021-09-15 Колюсід Фармасьютікалз, Інк. Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084949A1 (en) * 2002-03-29 2003-10-16 Eli Lilly And Company Pyridinoylpiperidines as 5-ht1f agonists
US20080300407A1 (en) 2002-03-29 2008-12-04 Eli Lilly And Company Pyridinoylpiperidines as 5-HT1F agonists
WO2006081127A2 (en) * 2005-01-24 2006-08-03 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid

Also Published As

Publication number Publication date
LT2413933T (lt) 2018-02-26
US20250228839A1 (en) 2025-07-17
HK1243923A1 (zh) 2018-07-27
NO2023002I1 (no) 2023-01-05
JP2016188241A (ja) 2016-11-04
SI2413933T2 (sl) 2021-09-30
HUE037261T2 (hu) 2018-08-28
CY2023001I2 (el) 2023-06-09
JP7110446B2 (ja) 2022-08-01
ES2655881T5 (es) 2021-11-25
PL2413933T5 (pl) 2021-10-18
CN102753171A (zh) 2012-10-24
JP5727457B2 (ja) 2015-06-03
JP2018087247A (ja) 2018-06-07
LUC00295I2 (enExample) 2025-09-22
LTC2413933I2 (enExample) 2025-03-10
US20210401822A1 (en) 2021-12-30
JP2025020117A (ja) 2025-02-12
US20100256187A1 (en) 2010-10-07
DK2413933T3 (da) 2018-01-29
FR23C1002I2 (fr) 2023-11-24
IL215483A0 (en) 2011-12-29
HRP20171742T1 (hr) 2018-02-09
MX2011010359A (es) 2012-02-23
AU2010232497A1 (en) 2011-11-24
EP2413933B1 (en) 2017-11-01
NL301214I1 (enExample) 2023-01-25
CA2757019C (en) 2018-05-15
JP2012522805A (ja) 2012-09-27
CN107412230A (zh) 2017-12-01
SI2413933T1 (en) 2018-04-30
FR23C1002I1 (fr) 2023-03-10
CY2023001I1 (el) 2023-03-24
JP2021152008A (ja) 2021-09-30
JP7566996B2 (ja) 2024-10-15
AU2010232497B2 (en) 2016-05-19
ES2655881T3 (es) 2018-02-22
WO2010115125A2 (en) 2010-10-07
JP2022163049A (ja) 2022-10-25
NO2413933T3 (enExample) 2018-03-31
JP2023175694A (ja) 2023-12-12
EP2413933A4 (en) 2012-09-19
WO2010115125A3 (en) 2011-02-17
EP2413933B2 (en) 2021-06-09
JP6887462B2 (ja) 2021-06-16
CY1119785T1 (el) 2018-06-27
NZ596161A (en) 2013-11-29
DK2413933T4 (da) 2021-08-23
JP2015013903A (ja) 2015-01-22
PT2413933T (pt) 2017-12-12
KR20110136893A (ko) 2011-12-21
HUS2300004I1 (hu) 2023-02-28
HRP20171742T4 (hr) 2021-08-06
LTPA2023502I1 (enExample) 2023-01-25
CA2757019A1 (en) 2010-10-07
IL215483A (en) 2017-07-31
EP2413933A2 (en) 2012-02-08
NL301214I2 (nl) 2023-04-19
US12257246B2 (en) 2025-03-25
FIC20230001I1 (fi) 2023-01-10
PL2413933T3 (pl) 2018-04-30
JP2019189617A (ja) 2019-10-31
JP7335397B2 (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
JP7335397B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドの組成物
Gristwood et al. Levobupivacaine: a new safer long acting local anaesthetic agent
DE602004005814T2 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
KR102372194B1 (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
CZ125198A3 (cs) Použití derivátu kyseliny pipekolinové a jeho farmaceuticky přijatelných solí pro výrobu léčiva pro ovlivňování neurologické aktivity u zvířete
KR20100016270A (ko) 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
JPH06508836A (ja) 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
US20020183241A1 (en) Methods for treating vertigo and motion sickness using descarboethoxyloratadine
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
US5929070A (en) Method for treating migraine pain with olanzapine
RU2298405C2 (ru) Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
KR20110005836A (ko) 과민성 방광의 치료를 위한 유데나필과 알푸조신 또는 옥시부티닌과의 복합제의 용도
Furukawa et al. Antiemetic effects of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-and apomorphine-induced emesis in dogs
HK1177139A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
Chowdhury et al. A study on the therapeutic efficacy of olopatadine hydrochloride in the management of allergic conjunctivitis
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
Lin Adjuvant Section 11 Analgesics and Antiemetics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20191227

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20210108

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20211221

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 8, Claim Number : 1 5, 13, 14 21, Period Limitation Text : 521, Comment Text : 14, 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 8, Claim Number : 1 5, 13, 14 21, Period Limitation Text : 521, Comment Text : 14, 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10